The BIO International conference presents an incredible opportunity to connect, build relationships and conduct business.

AbbVie's last deal of 2017 and first deal of 2018, both in Alzheimer's Disease and other neurodegenerative disorders, could mean that they are considering the vacuum left by Pfizer's neuroscience exit.

In our July 2017 profile of Gilead Sciences, we commented on their need to develop or acquire new blockbuster drugs. One month later, they did just that.

Here’s the thing - Most of those companies aren’t going to transact. They were never going to transact. And a thoughtful analysis would have shown you they weren’t going to transact before your team wasted months of executive time and company dollars flying to conferences and pointless meetings.

Artificial Intelligence provides opportunities to better understand and engage in a world saturated with data; empowering dealmakers to more deeply leverage their relationship expertise.

Gilead Sciences, Inc.
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: $9809M USD
Therapeutic Focus: HIV/AIDS, Liver Diseases, Hematology/Oncology, Inflammation/Respiratory, Infectious Diseases

Perhaps the best way to describe yesterday’s session on immuno-oncology, is to start at the end.

Just as the applause faded, the audience en masse rushed to the panelists, business cards in hand, hoping the brief exchange might lead to a transaction in the hottest area of biotech these days. And it could.

Oncology is dominating both interest from buyers and sellers in the marketplace, according to Neel Patel, Managing Director at Campbell Alliance, an inVenitv Health Company. That was one of the big takeaways from BIO's Tuesday Dealmakers’ Intentions: 2017 Market Outlook session.

“It’s not surprising to see the focus on oncology,” Dr. Paul Biondi, head of Business Development, Bristol-Myers Squibb, said.

“The company was a black box to me because I allowed my banker to actually deal with the company,” he said. And he hadn’t formed relationships with the senior officials of the company - people he could have called upon to try and salvage the deal.

Hasnain never made the same mistake again.

“It’s all about the relationships.”

Our team at MotionHall has translated one of the software industry’s most powerful sales practices to the life sciences business development process.

This June 2017, we’re excited to introduce you to predictive dealmaking - the smartest (and easiest) way to win biopharma deals, supported by MotionHall’s OutMatch AI.

Leading dealmakers understand that the challenge is not just to find a partner, but the right partner — one who will contribute to investor confidence and long-term success, more than immediate capital.

Here’s how they do it: